Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical ‌trials by the end of 2026, founder and CEO ‌Demis Hassabis said on ...

Jan 20 (Reuters) - Isomorphic Labs, ‌which uses artificial intelligence ‌for drug discovery, expects to have its first clinical trials by the ‍end of 2026, founder and CEO Demis Hassabis said ⁠on ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

Indicator species are living organisms that tell us that something has changed or is going to change in their environment. They can be easily observed, and studying them is considered a cost-effective ...

Brian Beers is a digital editor, writer, Emmy-nominated producer, and content expert with 15+ years of experience writing about corporate finance & accounting, fundamental analysis, and investing.

From the Department of Bizarre Anomalies: Microsoft has suppressed an unexplained anomaly on its network that was routing traffic destined to example.com—a domain reserved for testing purposes—to a ...